Ostabolin inhalation - Nektar Therapeutics/Zelos Therapeutics

Drug Profile

Ostabolin inhalation - Nektar Therapeutics/Zelos Therapeutics

Alternative Names: Cyclic hPTH-(1-31)-NH2 inhalation; Ostabolin-C inhalation; Ostabolin-C inhalation powder; Ostabolin-C pulmonary

Latest Information Update: 13 Oct 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nektar Therapeutics; Zelos Therapeutics Inc
  • Class Osteoporosis therapies; Peptide fragments; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 21 Oct 2008 Novartis agrees to acquire certain areas of pulmonary business from Nektar
  • 25 Sep 2007 Clinical data presented at the American Society for Bone and Mineral Research 29th Annual Meeting (ASBMR-2007) added to the adverse events, pharmacokinetics and Musculoskeletal Disorders pharmacodynamics sections ,
  • 21 Sep 2006 Phase-I clinical trials in Osteoporosis in Canada (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top